Summary:
Peters Medical Research NY, LLC is conducting a phase 3 multi-center, double-blind, randomized, placebo-controlled, parallel group evaluation of the efficacy, safety, and tolerability of bococizumab (pf-04950615), in reducing the occurrence of major cardiovascular events in high risk subjects.
Qualified Participants Must:
• Be on background lipid lowering treatment
•
Be at high risk of a CV event
Qualified Participants May Receive:
Compensation for time and travel, close medical attention, and access to new treatment